Reaction Biology Launches InVEST Screening Panel to Identify Drug Toxicity Effects of New Drug Candidates
Retrieved on:
Tuesday, March 22, 2022
MALVERN, Pa., March 22, 2022 /PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry- leading provider of drug discovery services, today announced the launch of its In Vitro Evaluation of Safety and Toxicity (InVEST) Panel, an early safety pharmacology tool that detects potential drug toxicity effects that may cause adverse drug reactions and hinder clinical development. The new group of assays adds to the more than 2,000 biochemical, cell-based, biophysical, and in vivo assays in the Reaction Biology drug discovery portfolio.
Key Points:
- The new group of assays adds to the more than 2,000 biochemical, cell-based, biophysical, and in vivo assays in the Reaction Biology drug discovery portfolio.
- "The InVEST panel is a significant addition to our expanding portfolio of end-to-end solutions supporting the discovery of new drug candidates from target research through preclinical candidate selection," said Haiching Ma, Ph.D., Chief Scientific Officer of Reaction Biology.
- "Safety pharmacology screening against our InVEST panel will enable our clients to detect potential toxicity issues and optimize targets, ultimately improving success rates in clinical trials and with regulatory submissions."
- Early safety profiling with the InVEST panel includes 35 clinically relevant targets of six target families for broad coverage of potential adverse drug effects.